breast cancersnon-small cell lung cancersHER2-driven cancerstrastuzumab emtansineChampions OncologystaurosporineHER2-targeting ADCs
…t in oncology, with alterations present in approximately 30% of breast cancers and 20% of non-small cell lung cancers. These alterations—rangi…